Selected research
Market Structure
Global Apatinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Apatinib market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Apatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Apatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Apatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Apatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Apatinib include Jiangsu Hengrui Medicine, LSK BioPartners, Bukwang Pharmaceutical Company and Advenchen Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Apatinib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Apatinib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Apatinib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Apatinib market size, projected growth trends, production technologies, key applications, and end-use industries.
Apatinib Segment by Company
Jiangsu Hengrui Medicine
LSK BioPartners
Bukwang Pharmaceutical Company
Advenchen Laboratories
Apatinib Segment by Type
0.25g/Pcs
0.425g/Pcs
0.375g/Pcs
Apatinib Segment by Application
Advanced Hepatocellular Carcinoma
Metastatic Breast Cancer
Metastatic Gastric Carcinoma
Others
Apatinib Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Apatinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Apatinib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Apatinib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Apatinib market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Apatinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Apatinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Apatinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 0.25g/Pcs
- 0.425g/Pcs
- 0.375g/Pcs
Applications
- Advanced Hepatocellular Carcinoma
- Metastatic Breast Cancer
- Metastatic Gastric Carcinoma
- Others
Companies covered
- Jiangsu Hengrui Medicine
- LSK BioPartners
- Bukwang Pharmaceutical Company
- Advenchen Laboratories
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Apatinib Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Apatinib Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Apatinib Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Apatinib Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Apatinib Market Dynamics
- 2.1 Apatinib Industry Trends
- 2.2 Apatinib Industry Drivers
- 2.3 Apatinib Industry Opportunities and Challenges
- 2.4 Apatinib Industry Restraints
3 Apatinib Market by Manufacturers
- 3.1 Global Apatinib Revenue by Manufacturers (2021-2026)
- 3.2 Global Apatinib Sales by Manufacturers (2021-2026)
- 3.3 Global Apatinib Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Apatinib Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Apatinib Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Apatinib Manufacturers, Product Type & Application
- 3.7 Global Apatinib Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Apatinib Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Apatinib Players Market Share by Revenue in 2025
- 3.8.3 2025 Apatinib Tier 1, Tier 2, and Tier 3
4 Apatinib Market by Type
- 4.1 Apatinib Type Introduction
- 4.1.1 0.25g/Pcs
- 4.1.2 0.425g/Pcs
- 4.1.3 0.375g/Pcs
- 4.2 Global Apatinib Sales by Type
- 4.2.1 Global Apatinib Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Apatinib Sales by Type (2021-2032)
- 4.2.3 Global Apatinib Sales Market Share by Type (2021-2032)
- 4.3 Global Apatinib Revenue by Type
- 4.3.1 Global Apatinib Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Apatinib Revenue by Type (2021-2032)
- 4.3.3 Global Apatinib Revenue Market Share by Type (2021-2032)
5 Apatinib Market by Application
- 5.1 Apatinib Application Introduction
- 5.1.1 Advanced Hepatocellular Carcinoma
- 5.1.2 Metastatic Breast Cancer
- 5.1.3 Metastatic Gastric Carcinoma
- 5.1.4 Others
- 5.2 Global Apatinib Sales by Application
- 5.2.1 Global Apatinib Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Apatinib Sales by Application (2021-2032)
- 5.2.3 Global Apatinib Sales Market Share by Application (2021-2032)
- 5.3 Global Apatinib Revenue by Application
- 5.3.1 Global Apatinib Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Apatinib Revenue by Application (2021-2032)
- 5.3.3 Global Apatinib Revenue Market Share by Application (2021-2032)
6 Global Apatinib Sales by Region
- 6.1 Global Apatinib Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Apatinib Sales by Region (2021-2032)
- 6.2.1 Global Apatinib Sales by Region (2021-2026)
- 6.2.2 Global Apatinib Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Apatinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Apatinib Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Apatinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Apatinib Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Apatinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Apatinib Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Apatinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Apatinib Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Apatinib Revenue by Region
- 7.1 Global Apatinib Revenue by Region
- 7.1.1 Global Apatinib Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Apatinib Revenue by Region (2021-2026)
- 7.1.3 Global Apatinib Revenue by Region (2027-2032)
- 7.1.4 Global Apatinib Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Apatinib Revenue (2021-2032)
- 7.2.2 North America Apatinib Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Apatinib Revenue (2021-2032)
- 7.3.2 Europe Apatinib Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Apatinib Revenue (2021-2032)
- 7.4.2 Asia-Pacific Apatinib Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Apatinib Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Apatinib Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Jiangsu Hengrui Medicine
- 8.1.1 Jiangsu Hengrui Medicine Company Information
- 8.1.2 Jiangsu Hengrui Medicine Business Overview
- 8.1.3 Jiangsu Hengrui Medicine Apatinib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Jiangsu Hengrui Medicine Apatinib Product Portfolio
- 8.1.5 Jiangsu Hengrui Medicine Recent Developments
- 8.2 LSK BioPartners
- 8.2.1 LSK BioPartners Company Information
- 8.2.2 LSK BioPartners Business Overview
- 8.2.3 LSK BioPartners Apatinib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 LSK BioPartners Apatinib Product Portfolio
- 8.2.5 LSK BioPartners Recent Developments
- 8.3 Bukwang Pharmaceutical Company
- 8.3.1 Bukwang Pharmaceutical Company Company Information
- 8.3.2 Bukwang Pharmaceutical Company Business Overview
- 8.3.3 Bukwang Pharmaceutical Company Apatinib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Bukwang Pharmaceutical Company Apatinib Product Portfolio
- 8.3.5 Bukwang Pharmaceutical Company Recent Developments
- 8.4 Advenchen Laboratories
- 8.4.1 Advenchen Laboratories Company Information
- 8.4.2 Advenchen Laboratories Business Overview
- 8.4.3 Advenchen Laboratories Apatinib Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Advenchen Laboratories Apatinib Product Portfolio
- 8.4.5 Advenchen Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Apatinib Value Chain Analysis
- 9.1.1 Apatinib Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Apatinib Production Mode & Process
- 9.2 Apatinib Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Apatinib Distributors
- 9.2.3 Apatinib Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst